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Abstract
Background
Gout is a common inflammatory arthritis associated with adverse clinical outcomes.
Under treatment is common in the general population. The aim of this study was to deter-
mine the prevalence of gout and its treatment among patients with chronic kidney disease
(CKD).
Methods
We conducted a multi-centre cross sectional study of patients (n = 522) who attended spe-
cialist nephrology clinics in Ireland. Standardized data collection tool recorded clinical char-
acteristics and medication use at clinic visits and kidney function was assessed with
standardised creatinine measurements and Estimated Glomerular Filtration Rate (eGFR).
The prevalence of gout and the corresponding use of urate lowering therapies (ULT) were
determined. Multivariate logistic regression explored correlates of gout expressed as Odds
Ratios (OR) and 95% Confidence Intervals (CI) adjusting for demographic and clinical
characteristics.
Results
Overall prevalence of gout was 16.6% and increased significantly from 7.5% in Stage 1–2
CKD to 22.8% in stage 4–5 CKD, P< 0.005. Prevalence increased with age (P < 0.005) and
was higher in men than women (19.1% versus 10.3% P< 0.005). Overall, 67.9% of gout
patients with CKD were treated with ULT, and the percentage increased with advancing
stage of CKD from 55.6% in Stage 1–2 to 77.4% in Stage 4–5, P<0.005. Multivariable
modelling identified men (vs women), OR, 1.95 (0.95–4.03), serum albumin, OR 1.09
(1.02–1.16) per 1 g/L lower, poorer kidney function, OR 1.11 (1.01–1.22) per 5 ml/min/
1.73m2 lower, and rising parathyroid hormone levels, OR 1.38 (1.08–1.77) per 50 pg/ml
higher as disease correlates.
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Conclusions
Gout is common in CKD and increases with worsening kidney function in the Irish health
system. Over two thirds of patients with gout were receiving ULT, increasing to 77% of
patients with advanced CKD. Greater awareness of gout in CKD, its treatment and the effec-
tiveness of treatment strategies should be vigorously monitored to improve patient
outcomes.
Introduction
Gout is a common inflammatory arthropathy caused by the deposition of monosodium urate
crystals in joints and soft tissues. In the general population, the prevalence of gout varies
worldwide from 0.1% to approximately 10% and incidence rates vary from 0.3 to 6 cases per
1,000 person-years [1]. In addition to causing excruciating arthritic pain, gout is associated
with premature death, classically explained by a high frequency of comorbid conditions, espe-
cially renal and cardiovascular diseases [2–4]. Gout is associated with a progressive functional
impairment, reduced quality of life, lost productivity and increased mortality [5,6]. Recent
observational studies implicate both hyperuricaemia and gout as possible risk factors for pro-
gression of chronic kidney disease (CKD) suggesting that the treatment of these conditions
may lead to measurable clinical benefits [7,8]. Several small clinical trials have found that treat-
ment with Urate-Lowering Therapy (ULT) reduced the progression of kidney disease [9,10].
Furthermore, a recent meta-analysis of clinical trials with over 1, 200 patients found that treat-
ment with ULT significantly reduced the risk of major renal and cardiovascular events [11].
This emerging evidence would suggest that treatment and control of gout is especially impor-
tant among patients with impaired kidney function.
Few studies have examined the burden of gout among individuals with impaired kidney
function in the general population or with CKD within the health system. A report from Krish-
nan using data from the 2009–2010 National Health and Nutrition Examination Survey
(NHANES) in the US found that the prevalence of self-reported gout increased from 2.9% in
patients with normal renal function to 33.3% among those with glomerular filtration rate
(eGFR) < 30 ml/min/1.73m2. Adjusting for confounding, individuals with severe renal
impairment had a 6-fold higher prevalence of gout compared to those with normal kidney
function [12]. Data from the German Chronic Kidney Disease (GCKD) cohort, a prospective
observational study of 5,085 patients, found a prevalence of 24.3% among patients with pre-
existing CKD which increased to 35.6% among those with GFR< 30 ml/min/1.73m2 [13].
These studies would suggest that gout is highly prevalent among patients with pre-existing
CKD and may contribute significantly to morbidity from arthropathy and accelerated kidney
disease progression. Despite these studies there are several unanswered questions with regard
to the burden of gout and its management among patients with CKD in the health system. For
example, it is unclear to what extent patients with gout who attend specialist renal clinics are
treated with ULT and whether treatment rates vary across stage of CKD.
Given the paucity of data on the burden and management of gout in health systems we con-
ducted a multicentre cross–sectional study to determine the prevalence of gout and concurrent
treatment strategies among CKD patients within the Irish health system.
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Materials and methods
Study design
This study was a multicentre cross-sectional study of adult patients with CKD treated at 18
adult specialist nephrology clinics during the first 2 weeks of December 2012 and 2013. All
nephrology clinics were invited to participate in the audit and a consecutive sampling
approach for patient selection was adopted. The clinics were geographically dispersed across
six health regions in the Republic of Ireland (West, Midwest, Northwest, Midlands, East and
Southeast). Patients less than 18 years of age or receiving dialysis were excluded. A standard-
ised data collection tool was used to capture anonymised clinical information from medical
case records, laboratory information systems and physician clinic letters. Demographic and
clinical characteristics were captured including primary cause of kidney disease, comorbid
medical conditions, prescribed medications and laboratory values recorded within the previ-
ous 3 months [or within 6 months for specific laboratory values for iron indices, parathyroid
hormone (PTH), lipids and haemoglobin A1c (HbA1c)]. The study was approved by the Ethics
Committee of University Hospital Limerick.
Definition of gout
Gout was defined as the presence of a documented clinical diagnosis of gout on medical case
records and/or physician clinic letters or if the patient was receiving ULT. The Estimated Glo-
merular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiol-
ogy Collaboration (CKD-EPI) equation [14] and CKD was classified according to the Kidney
Disease Improving Global Outcomes (KDIGO) guidelines [15]. The following eGFR categories
were defined:� 60 ml/min/1.73 m2 (Stages 1–2), 30–59 (Stage 3) and <30 (Stages 4–5).
Statistical methods
Descriptive statistics were calculated for continuous variables (reported as mean values and
standard deviations or median and IQR where appropriate) and categorical variables (reported
as numbers and percentages). Comparisons across groups were made using Fisher’s exact tests
for categorical variables and Kruskal-Wallis test for continuous variables. Multivariable logistic
regression models were fitted to explore the associations of demographic and clinical factors
with prevalent gout. Sequential age, and age and sex adjusted models were developed to exam-
ine relationships. The explanatory variables included age modelled as 5-year intervals, sex,
comorbid medical conditions, laboratory values recorded prior to clinic visit, and prescribed
medications. A final multivariate model was constructed to identify the relative contributions
of demographic, clinical and treatment factors with the presence of gout. Model performance
was assessed using the c-statistic and the adequacy of the logistic models was tested using the
Hosmer and Lemeshow goodness-of-fit test. Associations were expressed as odds ratios (ORs)
and 95% confidence intervals (CIs) and all analyses were performed using R statistical software
[16].
Results
Baseline characteristics of the study population
Table 1 outlines the basic characteristics of the study population by CKD stage. The majority
were men (55.2%), white Irish (95%) and the average age was 58.2 (SD 16.9). The average
eGFR was 48.4 (SD 27.7) ml/min/1.73 m2. The principal causes of CKD were hypertension
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Table 1. Baseline characteristics of the study population by stage of CKD.
Variable n Overall Cohort
(n = 522)
Stage 1–2
(n = 142)
Stage 3
(n = 176)
Stage 4–5
(n = 139)
P-value
Demographic
Age mean (SD) 515 58.2 (16.9) 48.8(14.5) 60.3(15.1) 66.3(15.7) <0.001
Sex
Men (%) 283 (55.2) 78.0 (54.9) 106.0 (60.2) 77.0 (55.4)
Women (%) 230 (44.8) 64.0 (45.1) 70.0 (39.8) 62.0 (44.6) 0.568
Race (%)
White Irish 479 (95.0) 126.0 (91.3) 168.0 (96.6) 132.0 (96.4) 0.051
White Irish traveller 2 (0.4) 1.0 (0.7) 0.0 (0.0) 0.0 (0.0) 0.054
White other 12 (2.4) 2.0 (1.4) 5.0 (2.9) 4.0 (2.9) 0.054
Asian 2 (0.4) 1.0 (0.7) 1.0 (0.6) 0.0 (0.0) 0.051
Other 9 (1.8) 8.0 (5.8) 0.0 (0.0) 1.0 (0.7) 0.052
Cause of CKD (%)
Hypertension 138 (26.8) 31.0 (21.8) 44.0 (25.0) 48.0 (34.5) 0.045
Diabetes 62 (12.0) 12.0 (8.5) 25.0 (14.2) 23.0 (16.5) 0.105
Glomerulonephritis 93 (18.1) 35.0 (24.6) 26.0 (14.8) 21.0 (15.1) 0.052
Autosomal dominant PKD 33 (6.4) 7.0 (4.9) 16.0 (9.1) 7.0 (5.0) 0.253
Hereditary nephritis 13 (2.5) 5.0 (3.5) 6.0 (3.4) 1.0 (0.7) 0.257
Other cause of CKD 168 (32.6) 53.0 (37.3) 58.0 (33.0) 43.0 (30.9) 0.496
Not known 70 (13.6) 16.0 (11.3) 18.0 (10.2) 23.0 (16.5) 0.231
Biopsy (%)
Native Kidney biopsy 75 (14.4) 27.0 (19.0) 26.0 (14.8) 18.0 (12.9) 0.363
Comorbid Conditions (%)
Gout 78 (16.6) 9.0 (7.5) 29.0 (17.8) 31.0 (22.8) 0.003
Diabetes 106 (22.6) 21.0 (17.6) 38.0 (23.2) 38.0 (27.9) 0.148
Hypertension 370 (78.7) 87.0 (73.1) 131.0 (79.9) 114.0 (83.8) 0.108
Cancer 33 (7.0) 9.0 (7.6) 13.0 (7.9) 9.0 (6.6) 0.919
Heart failure 22 (4.7) 2.0 (1.7) 7.0 (4.3) 10.0 (7.4) 0.105
Thyroid disease 48 (10.2) 7.0 (5.9) 19.0 (11.6) 18.0 (13.2) 0.124
Stroke or Transient ischaemic attack 22 (4.7) 4.0 (3.4) 7.0 (4.3) 9.0 (6.6) 0.483
Chronic obstructive airways disease 22 (4.7) 4.0 (3.4) 7.0 (4.3) 8.0 (5.9) 0.607
Peripheral vascular disease 38 (8.1) 4.0 (3.4) 17.0 (10.4) 15.0 (11.0) 0.042
Coronary heart disease 75 (16.0) 11.0 (9.2) 26.0 (16.0) 33.0 (24.3) 0.005
Obesity 28 (6.0) 5.0 (4.2) 8.0 (4.9) 12.0 (8.8) 0.262
Hypercholesterolemia 127 (27.1) 28.0 (23.3) 48.0 (29.4) 43.0 (32.1) 0.287
Depression 20 (4.3) 6.0 (5.0) 6.0 (3.7) 7.0 (5.1) 0.791
Arthritis 27 (5.7) 6.0 (5.0) 11.0 (6.7) 6.0 (4.4) 0.689
Osteoporosis 30 (6.4) 7.0 (5.9) 16.0 (9.8) 4.0 (2.9) 0.053
Current or ex-smoker 52 (11.1) 15.0 (12.6) 20.0 (12.2) 12.0 (8.8) 0.583
Physical Measurements
Weight (kg) 397 80.7 (17.5) 79.8 (15.9) 79.8 (17.6) 82.2 (19.5) 0.748
Pulse (beats/min) 293 75.2 (16.3) 75.6 (13.1) 73.6 (13.6) 75.7 (19.3) 0.473
Systolic BP (mmHg) 481 137.7 (19.6) 131.8 (16.6) 138.5 (19.0) 141.7 (21.7) <0.001
Diastolic BP (mmHg) 481 77.7 (13.3) 78.7 (13.8) 77.7 (12.9) 76.7 (12.3) 0.302
Urine tests
Protein: creatinine ratio 136 136.0 (246.8) 49.0 (71.3) 150.1 (348.0) 209.7 (226.3) <0.001
Albumin: creatinine ratio 51 101.9 (214.9) 22.7 (28.1) 93.4 (239.2) 208.2 (280.0) 0.004
(Continued)
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(26.8%), glomerulonephritis (18.1%) and diabetes (12%), although for a large proportion the
primary cause was classified as unknown in 13.6%.
Prevalence of gout
The overall prevalence of gout in the entire cohort was 16.6% and increased significantly from
7.5% in CKD stages 1–2 to 22.8% in CKD stages 4–5, p< 0.005 (Fig 1). When gout was defined
Table 1. (Continued)
Variable n Overall Cohort
(n = 522)
Stage 1–2
(n = 142)
Stage 3
(n = 176)
Stage 4–5
(n = 139)
P-value
Prescribed Medications (%)
ACE-I 114 (21.8) 37.0 (26.1) 45.0 (25.6) 21.0 (15.1) 0.040
ARB 93 (17.8) 27.0 (19.0) 34.0 (19.3) 26.0 (18.7) 0.999
ACE-I & ARB 11 (2.1) 3.0 (2.1) 6.0 (3.4) 1.0 (0.7) 0.290
ACE-I or ARB 196 (37.5) 61.0 (43.0) 73.0 (41.5) 46.0 (33.1) 0.187
Aspirin 169 (32.4) 34.0 (23.9) 59.0 (33.5) 63.0 (45.3) 0.001
Beta- blocker 147 (28.2) 36.0 (25.4) 52.0 (29.5) 47.0 (33.8) 0.297
Calcium blocker 152 (29.1) 32.0 (22.5) 52.0 (29.5) 50.0 (36.0) 0.045
Diuretic 121 (23.2) 17.0 (12.0) 37.0 (21.0) 54.0 (38.8) <0.001
Statin 169 (32.4) 36.0 (25.4) 64.0 (36.4) 57.0 (41.0) 0.016
Vasodilator 18 (3.4) 2.0 (1.4) 7.0 (4.0) 8.0 (5.8) 0.134
Gout-specific medications (%)
Urate lowering therapies 53 (10.2) 5.0 (3.5) 17.0 (9.7) 24.0 (17.3) <0.001
Allopurinol 49 (9.4) 4.0 (2.8) 15.0 (8.5) 23.0 (16.5) 0.001
Febuxostat 4 (0.8) 1.0 (0.7) 2.0 (1.1) 1.0 (0.7) 0.999
Acute Flare /flare prophylaxis
Colchicine 4 (0.8) 0.0 (0.0) 2.0 (1.1) 0.0 (0.0) 0.340
Corticosteroid 21 (4.0) 5.0 (3.5) 11.0 (6.2) 2.0 (1.4) 0.093
NSAIDs 4 (0.8) 2.0 (1.4) 1.0 (0.6) 0.0 (0.0) 0.507
PKD, polycystic kidney disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; NSAID, non-steroidal anti-inflammatory medication
https://doi.org/10.1371/journal.pone.0210487.t001
Fig 1. Prevalence of gout by CKD stage and age group. (a) Prevalence of gout by CKD stage groups (b) Prevalence of
gout by age group; a proportional trend test was used to assess the linear trend in the proportion of gout cases across
age categories.
https://doi.org/10.1371/journal.pone.0210487.g001
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solely by a medical record diagnosis, the prevalence of gout and by CKD stage followed a simi-
lar trend (S1 Appendix). The baseline characteristics of the study population by presence or
absence of gout are shown in Table 2. Patients with gout were significantly older, predomi-
nantly men, and had significantly higher prevalence of coronary disease than those without
gout (p<0.005). Overall frequency of gout increased with advancing age; from 7.5% in patients
age< 44 years to 19.5% for patients age> 71 years, p<0.005. Compared to patients without
gout, those with gout had significantly lower eGFR values [36.3 (19.8) versus 48.1 (26.9) ml/
min/1.73m2 (p< 0.005) and significantly greater proteinuria [protein/creatinine ratio 323.4
(571) mg/mmol versus 116.1 (174) respectively, all p< 0.01]. Gout patients also experienced
significantly lower serum albumin concentrations and significantly higher parathyroid hor-
mone concentrations than those without gout, all p<0.001.
Gout-specific medications
Overall, 67.9% of patients with gout were receiving ULT as shown in Table 2 and the preva-
lence of ULT use increased from 55.6% in Stages 1–2 to 58.6 % in Stage 3 and to 77.4 % in
Stages 4–5 (p = 0.002). Allopurinol was the most commonly prescribed ULT (62.8%) with a
much smaller percentage treated with Febuxostat (5.1%). Colchicine use was recorded in 5.1%
of patients while a further 7.7% of gout patients were receiving corticosteroids. None of the
patients with gout were recorded as using non-steroidal anti-inflammatory drugs (NSAIDS).
Correlates of gout
The relationship of demographic and clinical factors with gout is illustrated in Table 3. With
adjustment only for age and sex; advancing age [1.11 (95% CI 1.02–1.20) for every 5-year
increase], male gender [OR 1.85 (1.09–3.12)] and patients with coronary disease [OR 1.94
(1.05–3.58)] were significantly more likely to have gout. Worsening kidney function increased
the likelihood of having gout [OR 1.10 (1.03–1.17) for each 5 ml/min/1.73m2 decrease in
eGFR]. Similarly, higher levels of proteinuria quantified by protein/creatinine ratio estimation
were correlated with greater likelihood of gout [log2 PCR 1.45 (1.09–1.93), p<0.05). Lower
serum albumin levels and worsening secondary hyperparathyroidism were also associated
with greater likelihood of gout [OR 1.09 (1.03–1.14) per 1 g/dL decrease in albumin, and OR
1.33 (1.14–1.56) per 50 pg/mL increase in PTH, all p<0.005. Use of diuretics and beta-block-
ers also correlated with gout [OR 2.72 (1.61–4.60) and OR 1.81 (1.08–3.02) respectively.
In the fully adjusted model, lower eGFR and worsening serum albumin remained signifi-
cant correlates of gout as illustrated in Table 4. Given that PTH values were available for a
smaller percentage of patients (n = 162), an additional analysis was performed in which we
restricted to the final model to those with valid PTH concentrations. In this restricted model, a
rising PTH concentration was also significant [OR 1.38, (1.08–1.77) per 50 pg/mL increase,
p = 0.01. This model had a C-statistic of 0.83.
Discussion
In this large multi-centre study, we found a substantial burden of gout among Irish patients
with CKD (16.6%) that increased significantly from 7.5% in patients with mild CKD to 22.8%
among patients with moderate to severe CKD (eGFR< 30 ml/min/1.73m2). Gout was more
common in men than in women and rates increased with advancing age. Adjusting for differ-
ences in age and sex, we found that patients with lower kidney function, lower serum albumin,
and worsening secondary hyperparathyroidism were more likely to have gout. Overall, almost
68% of gout patients with CKD were receiving ULT agents, with allopurinol being the most
commonly prescribed ULT. Importantly and encouragingly, we observed a significant trend of
Prevalence and treatment of gout in CKD in the Irish health system: A national study
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Table 2. Baseline characteristics of the study population by presence or absence of Gout.
Variable n Overall Cohort
(n = 522)
No Gout
(n = 393)
Gout
(n = 78)
P-value
Demographic factors
Age mean (SD) 515 58.2(16.9) 58.8(16.6) 63.9(13.6) 0.021
Sex
Men (%) 283 (55.2) 214 (54.7) 54 (69.2)
Women (%) 230 (44.8) 177 (45.3) 24 (30.8) 0.024
Race (%)
White Irish 479 (95.0) 368 (95.8) 74 (96.1) 0.756
White Irish traveller 2 (0.4) 2 (0.5) 0 (0.0) 0.761
White other 12 (2.4) 5 (1.3) 3 (3.9) 0.756
Asian 2 (0.4) 2 (0.5) 0 (0.0) 0.76
Other 9 (1.8) 7 (1.8) 0 (0.0) 0.755
Cause of CKD (%)
Hypertension 138 (26.8) 117 (29.8) 18 (23.1) 0.273
Diabetes 62 (12.0) 49 (12.5) 13 (16.7) 0.358
Glomerulonephritis 93 (18.1) 66 (16.8) 17 (21.8) 0.328
Autosomal dominant PKD 33 (6.4) 26 (6.6) 6 (7.7) 0.805
Hereditary nephritis 13 (2.5) 12 (3.1) 1 (1.3) 0.704
Other cause of CKD 168 (32.6) 129 (32.8) 22 (28.2) 0.507
Not known 70 (13.6) 49 (12.5) 12 (15.4) 0.464
Biopsy (%)
Native kidney biopsy 75 (14.4) 60 (15.3) 9 (11.5) 0.485
Comorbid Conditions (%)
Diabetes 106 (22.6) 87 (22.2) 19 (24.7) 0.656
Hypertension 370 (78.7) 306 (78.1) 63 (81.8) 0.544
Cancer 33 (7.0) 27 (6.9) 6 (7.8) 0.807
Heart failure 22 (4.7) 19 (4.9) 3 (3.9) 0.999
Thyroid disease 48 (10.2) 42 (10.7) 6 (7.8) 0.54
Stroke or Transient ischaemic attack 22 (4.7) 21 (5.4) 1 (1.3) 0.149
Chronic obstructive airways disease 22 (4.7) 18 (4.6) 4 (5.2) 0.77
Peripheral vascular disease 38 (8.1) 32 (8.2) 6 (7.8) 0.999
Coronary heart disease 75 (16.0) 52 (13.3) 22 (28.6) 0.002
Obesity 28 (6.0) 22 (5.6) 6 (7.8) 0.435
Hypercholesterolaemia 127 (27.1) 106 (27.1) 21 (27.3) 0.999
Depression 20 (4.3) 20 (5.1) 0 (0.0) 0.057
Arthritis 27 (5.7) 23 (5.9) 4 (5.2) 0.999
Osteoporosis 30 (6.4) 25 (6.4) 5 (6.5) 0.999
Current or ex-smoker 52 (11.1) 44 (11.2) 8 (10.4) 0.999
Obesity 28 (6.0) 22 (5.6) 6 (7.8) 0.435
Physical Measurements
Weight (kg) 397 80.7(17.5) 80.1(16.0) 86.7(23.1) 0.094
Pulse (beats/min) 293 75.2(16.3) 74.7(16.2) 76.8(18.2) 0.569
Systolic BP (mmHg) 481 137.7(19.6) 137.8(18.8) 140.2(22.5) 0.576
Diastolic BP (mmHg) 481 77.7(13.3) 77.6(13.7) 78.6(12.1) 0.826
Laboratory Measures
eGFR (mL/min/1.73m2) 457 48.4 (27.7) 48.1 (26.9) 36.3 (19.8) 0.001
Haemoglobin (g/dL) 448 12.6 (1.9) 12.6 (1.9) 12.5 (1.8) 0.289
(Continued)
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increasing ULT use from 55.6% in Stage 1–2 to 77.4% in Stage 4–5, evidence that supports bet-
ter recognition and treatment of gout in this high-risk population.
Recent studies have identified strong relationships between gout and CKD, which are not
surprising given that hyperuricaemia, the principal driver of gout, is an inevitable consequence
Table 2. (Continued)
Variable n Overall Cohort
(n = 522)
No Gout
(n = 393)
Gout
(n = 78)
P-value
Ferritin (ng/L) 157 253.1 (339.4) 268.6 (361.3) 205.8 (194.9) 0.799
TSAT ratio (%) 126 26.7 (13.4) 27.6 (13.9) 22.9 (8.5) 0.184
Folate (nmol/L) 95 40.2 (143.7) 38.1 (137.8) 58.6 (190.4) 0.215
Vitamin B12 (nmol/L) 119 460.1 (272.1) 471.4 (287.1) 451.2 (160.2) 0.617
Corrected Calcium (mmol/L) 144 2.3 (0.2) 2.3 (0.1) 2.3 (0.3) 0.528
Calcium (mmol/L) 405 2.4 (0.2) 2.4 (0.2) 2.3 (0.1) 0.701
Albumin (g/L) 354 41.1 (5.6) 41.4 (5.8) 38.6 (4.6) <0.001
Phosphate (mmol/L) 376 1.1 (0.3) 1.1 (0.3) 1.2 (0.3) 0.068
Parathyroid hormone (PTH) (pg/mL) 162 130.6(129.1) 109.8 (95.1) 230.3 (199.6) <0.001
Total cholesterol (mmol/L) 192 4.6 (1.4) 4.6 (1.4) 4.5 (1.1) 0.783
LDL cholesterol (mmol/L) 124 2.6(1.2) 2.6(1.2) 2.1(0.6) 0.106
HDL cholesterol (mmol/L) 126 1.4(0.5) 1.4(0.5) 1.3(0.4) 0.728
Triglycerides (mmol/L) 190 4.0(21.6) 3.1(17.3) 2.6(1.7) 0.005
HbA1c (mmol/mol) 79 51.6(21.1) 52.5(22.0) 52.5(17.8) 0.850
Urine tests
Protein: creatinine ratio 136 136.0(246.8) 116.1(173.8) 323.4(571.3) 0.009
Albumin: creatinine ratio 51 101.9(214.9) 116.8(233.9) 38.4(33.2) 0.999
Medications (%)
ACE-I 114 (21.8) 93 (23.7) 17 (21.8) 0.772
ARB 93 (17.8) 75 (19.1) 15 (19.2) 0.999
ACE-I & ARB 11 (2.1) 9 (2.3) 2 (2.6) 0.999
ACE-I or ARB 196 (37.5) 159 (40.5) 30 (38.5) 0.801
Aspirin 169 (32.4) 133 (33.8) 31 (39.7) 0.363
Alpha Blocker 18 (3.4) 17 (4.3) 0 (0.0) 0.089
Beta Blocker 147 (28.2) 108 (27.5) 34 (43.6) 0.007
Calcium blocker 152 (29.1) 126 (32.1) 21 (26.9) 0.423
Diuretic 121 (23.2) 84 (21.4) 35 (44.9) <0.001
Statin 169 (32.4) 140 (35.6) 26 (33.3) 0.795
Gout-specific Medications (%)
Urate-lowering therapies 53 (10.2) 0 (0.0) 53 (67.9) <0.001
Allopurinol 49 (9.4) 0 (0.0) 49 (62.8) <0.001
Febuxostat 4 (0.8) 0 (0.0) 4 (5.1) 0.001
Probenecid 0 0 0 0 NA
Acute flare/flare prophylaxis
Colchicine 4 (0.8) 0 (0.0) 4 (5.1) 0.001
Corticosteroid 21 (4.0) 15 (3.8) 6 (7.7) 0.136
NSAIDs 4 (0.8) 3 (0.8) 0 (0.0) 0.999
PKD, polycystic kidney disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker: NSAIDs, Nonsteroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate was calculated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation.
https://doi.org/10.1371/journal.pone.0210487.t002
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Table 3. Unadjusted, and age- and sex-adjusted Odd Ratios and 95% confidence intervals for gout.
Variable N OR (95% CI) P-value N AOR (95% CI)1 P-value
Demographics
Age per 5 year increase 471 1.11 (1.02–1.2) 0.012 469 1.11 (1.02–1.2) 0.013
Male vs Female 469 1.86 (1.11–3.13) 0.019 469 1.85 (1.09–3.12) 0.022
Comorbid Conditions
Diabetes 469 1.15 (0.65–2.03) 0.634 467 0.95 (0.52–1.71) 0.851
Hypertension 469 1.26 (0.68–2.37) 0.463 467 1.14 (0.6–2.16) 0.682
Cancer 469 1.14 (0.46–2.87) 0.777 467 0.89 (0.35–2.29) 0.813
Heart failure 468 0.79 (0.23–2.75) 0.716 466 0.66 (0.19–2.32) 0.519
Thyroid disease 469 0.70 (0.29–1.72) 0.441 467 0.67 (0.27–1.67) 0.388
Stroke or Transient ischaemic attack 469 0.23 (0.03–1.75) 0.157 467 0.21 (0.03–1.57) 0.127
Chronic obstructive airways disease 469 1.14 (0.37–3.46) 0.819 467 1.07 (0.35–3.3) 0.910
Peripheral vascular disease 469 0.95 (0.38–2.36) 0.913 467 0.69 (0.27–1.75) 0.438
Coronary heart disease 468 2.61 (1.47–4.63) 0.001 466 1.94 (1.05–3.58) 0.034
Obesity 469 1.42 (0.56–3.63) 0.462 467 1.21 (0.47–3.13) 0.694
Hypercholesterolaemia 468 1.01 (0.58–1.75) 0.977 466 0.90 (0.52–1.58) 0.725
Depression 469 0.88 (0.3–2.62) 0.817 467 0.80 (0.26–2.42) 0.690
Arthritis 469 1.02 (0.38–2.75) 0.970 467 0.97 (0.35–2.68) 0.960
Osteoporosis 469 0.92 (0.41–2.03) 0.831 467 0.95 (0.42–2.12) 0.892
Laboratory Variables
eGFR per 5 ml/min/1.73m2 decrease 419 1.11 (1.04–1.18) 0.001 419 1.10 (1.03–1.17) 0.005
Haemoglobin per 1 g/dL increase 413 0.96 (0.83–1.1) 0.530 411 0.98 (0.85–1.14) 0.838
Ferritin per 1 ng/L increase 151 1.00 (1.00–1.00) 0.450 151 1.00 (1.00–1.00) 0.520
TSAT ratio per 1% increase 121 0.97 (0.92–1.01) 0.167 121 0.97 (0.93–1.02) 0.271
Folate per 1 nmol/L increase 92 1.00 (1.00–1.00) 0.631 92 1.00 (1.00–1.00) 0.499
Vitamin B12 per 1 nmol/L increase 114 1.00 (1.00–1.00) 0.796 114 1.00 (1.00–1.00) 0.892
Calcium (mmol/L) 373 0.56 (0.1–3.04) 0.504 371 0.83 (0.14–4.73) 0.830
Serum Albumin per 1 g/L decrease 327 1.08 (1.03–1.13) 0.002 325 1.09 (1.03–1.14) 0.001
Phosphate per 1 mmol/L increase 346 2.57 (0.97–6.83) 0.059 344 2.43 (0.87–6.81) 0.091
PTH per 50 pg/mL increase 157 1.34 (1.15–1.57) <0.001 156 1.33 (1.14–1.56) <0.001
Total cholesterol per 1 mmol/L increase 181 0.92 (0.64–1.32) 0.652 180 1.01 (0.69–1.47) 0.976
LDL cholesterol per 1 mmol/L increase 118 0.55 (0.27–1.15) 0.112 117 0.55 (0.26–1.15) 0.114
HDL cholesterol per 1mmol/L increase 120 0.63 (0.17–2.38) 0.495 119 0.65 (0.16–2.66) 0.545
Triglycerides per 1 mmol/L increase 179 1.00 (0.96–1.03) 0.888 178 1.00 (0.96–1.03) 0.837
HbA1c per 1 mmol/mol increase 75 1.00 (0.97–1.03) 0.993 75 1.00 (0.97–1.03) 0.961
log2(PCR) 125 1.43 (1.08–1.9) 0.012 124 1.45 (1.09–1.93) 0.011
Medications
ACE-I 471 0.90 (0.50–1.61) 0.722 469 0.87 (0.48–1.6) 0.665
ARB 471 1.01 (0.54–1.87) 0.976 469 1.19 (0.63–2.25) 0.594
Aspirin 471 1.29 (0.78–2.12) 0.318 469 0.94 (0.55–1.61) 0.829
Beta Blocker 471 2.04 (1.24–3.36) 0.005 469 1.81 (1.08–3.02) 0.023
Calcium blocker 471 0.78 (0.45–1.34) 0.372 469 0.72 (0.41–1.25) 0.243
Diuretic 471 2.99 (1.80–4.97) <0.001 469 2.72 (1.61–4.60) <0.001
Statin 471 0.90 (0.54–1.51) 0.699 469 0.76 (0.45–1.29) 0.306
LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker: NSAIDs,
Nonsteroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI).
1AOR: adjusted for age and sex only
https://doi.org/10.1371/journal.pone.0210487.t003
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of worsening kidney function [17]. However, only few have quantified the burden of gout and
corresponding rates of ULT treatment among patients with pre-existing CKD. In our study,
we describe a substantial burden of gout in CKD patients attending specialist clinics in the
Irish health system. Our estimate (16.6%) is somewhat lower than that reported by the German
Chronic Kidney Disease study (24.3%), which may reflect underlying differences in prevalence
in the general population from respective countries or differences in rates of death among
gout patients with CKD [13]. However, the pattern of increase in gout prevalence from early
CKD to advanced CKD followed near identical trends in both studies with an approximately
3-fold rise in prevalence. These results suggest that at the very least that gout is an extremely
common but treatable comorbidity among CKD patients who are already under clinical sur-
veillance in the health system.
Our study provides novel insights into the range and extent of treatment strategies for
patients with gout managed by kidney specialists in the Irish health system. We report overall
treatment rates of 68% for ULT among gout patients with CKD, which are identical to those
reported by the German CKD cohort (67%). However, unlike Germany, the principal ULT in
Ireland were uricostatic (predominantly allopurinol), as no patient was recorded as receiving
uricosuric therapy. Encouragingly, we reveal that rates of ULT use have increased from 55.6%
among patients in CKD stage 1–2 to 77.4% for patients with more advanced CKD 4–5 suggest-
ing a propensity to greater ULT prescribing. This trend in prescribing patterns may reflect the
increasing recognition by kidney specialists in Ireland that gout is eminently treatable or that
gout and/or hyperuricaemia are emerging risk factors for CKD progression [7–11]. It is equally
noteworthy, that colchicine (5.1%) and corticosteroids (7.7%) were the standard therapies for
acute flare or flare prophylaxis with no recorded use of NSAIDs. This new data highlights a
positive practice pattern that supports avoidance of nephrotoxic medications and kidney func-
tion preservation [15].
Despite the moderately high proportion of CKD patients with gout receiving ULT therapy
in this study, a substantial proportion of patients (~32%) nevertheless were untreated. Studies
have consistently shown that the treatment of gout is suboptimal in the general population
[18]. Prescription rates of ULT vary substantially from as low as 23% (Taiwan), 38% (UK) and
42% (Sweden) to a spectacular 80% in South Korea [19–21]. Low treatment rates among
patients with CKD may be partially explained by the presence of absolute and relative contra-
indications to the medications, as well as a lack of drug efficacy [22]. Additionally, dietary and
Table 4. Multivariable Odds Ratio for gout among patients with CKD in the Irish health system.
Variable AOR (95% CI) P-value AOR (95% CI) P-value
Model 1 (N = 286) Model 2 (N = 126)
Age per 5 year increase 1.09 (0.96–1.24) 0.185 1.00 (0.82–1.21) 0.962
Male vs Female 1.95 (0.95–4.03) 0.070 2.99 (0.79–11.33) 0.107
Coronary Heart Disease 1.57 (0.68–3.63) 0.291 1.47 (0.37–5.76) 0.583
Diuretic use 1.79 (0.87–3.68) 0.111 0.78 (0.20–2.95) 0.710
eGFR per 5 ml/min/1/73m2 decrease 1.11 (1.01–1.22) 0.037 1.03 (0.85–1.23) 0.792
Serum albumin per 1 g/L decrease 1.09 (1.02–1.16) 0.008 1.15 (1.01–1.30) 0.040
Serum phosphate per 1 mmol/l increase 0.34 (0.08–1.46) 0.147 0.40 (0.04–4.20) 0.445
Parathyroid hormone per 50 pg/mL increase – 1.38 (1.08–1.77) 0.011
Model 1: adjusted for continuous variables (age, eGFR, serum albumin, serum phosphate) and categorical variables (sex, history of coronary heart disease and diuretic
use). The model had a C-statistic 0.77 and there was no evidence of poor fit from the Hosmer and Lemeshow goodness of fit test (p = 0.6). Model 2: adjusted for all
variables as Model 1 in addition to serum parathyroid hormone (PTH). This model had a C-statistic of 0.83 and there was no evidence of poor fit from the Hosmer and
Lemeshow goodness of fit test (p = 0.9).
https://doi.org/10.1371/journal.pone.0210487.t004
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lifestyle interventions may account for those not undertaking ULT. Dietary modification is
typically suggested as part of the initial treatment for patients with gout, although some suggest
it should be ancillary to ULT [23]. Prior to the availability of febuxostat, allopurinol was the
principal ULT for patients with gout and impaired renal function. However, the risk of allopu-
rinol hypersensitivity syndrome (AHS) is increased in renal impairment and consequently lin-
gering concerns regarding this infrequent but potentially lethal event may contribute to ULT
avoidance in CKD patients [24,25].
Prior studies have identified strong relationships between hyperuricaemia, the precursor to
gout, and several metabolic markers [26]. In the current study, we observed for the first time
an inverse relationship between serum albumin and gout. In the final adjusted model, for each
1 g/L lower serum albumin, the likelihood of gout increased by 9%. Low serum albumin may
reflect protein-losing states, poor nutritional status, or systemic inflammation. Prior studies
have also identified an independent relationship between serum uric acid and the extent of
albuminuria [27–30]. Tseng and colleagues have reported positive increases in urinary albu-
minuria with increasing serum uric acid concentrations in type 2 diabetes [27] while prospec-
tively designed cohorts have confirmed the predictive impact of hyperuricaemia on
albuminuria [28–30]. Serum albumin is a negative acute phase reactant, and thus low serum
albumin levels may also reflect ongoing systemic inflammation associated with gout.
We also uncovered a very strong independent association between elevated PTH and the
occurrence of gout. This is an intriguing finding, which suggests that progressive secondary
hyperparathyroidism serves to increase the likelihood of gout in the setting of CKD. Previous
studies have suggested a strong biological influence of PTH on serum uric acid levels possibly
mediated by reduced renal excretion of uric acid [31–35]. However, in virtually all of these
studies, hyperparathyroidism was primary in nature, and correction of which led to a fall in
uric acid concentrations [31,32]. Our study not only extends the observations of previous insti-
gators but for the first time associates secondary hyperparathyroidism of CKD with clinical
gout. Indeed in our analysis, a rising serum PTH level was a stronger correlate of gout than
worsening eGFR, suggesting a strong pathobiological basis.
Our study is not with limitations. First, the design of the study was cross-sectional in nature
with reliance on medical records for data extraction. Therefore, we cannot infer causality
between explanatory covariates and gout. Second, although joint aspiration for monosodium
urate crystals remains the gold standard for diagnosis in clinical practice, our study relied on a
clinical diagnosis from medical records based on physician-diagnosis and/or use of ULT.
Inclusion of ULT medications ensured greater capture of clinical gout that may not have been
recorded on the patient’s medical record. Third, we lacked data on serum uric acid concentra-
tions, and thus were unable to correlate gout or ULT use with target thresholds. Notwithstand-
ing these limitations, the study was multicentre, with participation from a diverse range of
nephrology clinics across Ireland, thus strengthening the generalisability. Although a probabil-
ity sampling strategy would have been preferred, we argue that the application of consecutive
sampling to a homogenous population, attending renal clinics across multiple sites reduces
bias in relation to the representativeness of the study population. The large sample included a
detailed description of patient characteristics including comorbid conditions, measures of kid-
ney function including proteinuria. Finally, our analysis included a detailed description of cur-
rent prescribed ULT medications as well as medications for acute flares and flare prophylaxis.
Conclusion
In conclusion, our findings demonstrate a substantial burden of gout among patients with
CKD in the Irish health system that increases with advancing CKD. Male gender, worsening
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kidney function, malnutrition and secondary hyperparathyroidism were identified as indepen-
dent correlates. Almost 68% of patients with CKD were receiving ULT that increased to 77%
among patients with Stage 4–5 CKD. Patients with both gout and CKD represent a high-risk
group for considerable morbidity and mortality, compounded by the individual contribution
of each to adverse clinical outcomes. Given the substantial burden of gout in CKD patients,
greater awareness, screening and treatment of gout are key to improving patient outcomes in
this population. Future studies should examine dosing of ULT among CKD patients and the
extent to which treatment targets are achieved in order to prevent the complications of gout
and potentially slow the progression of CKD.
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